Psoriasis Symptoms and Impacts Measure (P-SIM) responses from the BE SURE bimekizumab in moderate to severe plaque psoriasis phase 3 trial

被引：0
|
作者：
Warren, Richard B. [1 ]
Augustin, Matthias [2 ]
Gottlieb, Alice B. [3 ]
Duffin, Kristina Callis [4 ]
Ciaravino, Valerie [5 ]
Cioffi, Christopher [6 ]
Peterson, Luke [6 ]
Blauvelt, Andrew [7 ]
机构：
[1] Univ Manchester, Dermatol Ctr, Salford Royal NHS Fdn Trust, Manchester NIHR Biomed Res Ctr, Manchester, Lancs, England
[2] Univ Med Ctr Hamburg Eppendorf UKE, Inst Hlth Serv Res Dermatol & Nursing IVDP, Hamburg, Germany
[3] Icahn Sch Med Mt Sinai, New York, NY 10029 USA
[4] Univ Utah, Dept Dermatol, Salt Lake City, UT USA
[5] UCB Pharma, Colombes, France
[6] UCB Pharma, Raleigh, NC USA
[7] Oregon Med Res Ctr, Portland, OR USA
来源：
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY | 2021年 / 85卷 / 03期
关键词：
D O I：
暂无
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
27373
引用
收藏
页码：AB138 / AB138
页数：1
相关论文
共 50 条
  • [41] Bimekizumab vs adalimumab in plaque psoriasis: Higher efficacy translates into improvements in quality of life in the BE SURE multicenter, randomized, double-blinded phase 3 trial
    Blauvelt, Andrew
    Thaci, Diamant
    Papp, Kim A.
    Merola, Joseph F.
    Cullen, Eva
    Vanvoorden, Veerle
    Ciaravino, Valerie
    Peterson, Luke
    Gordon, Kenneth
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2021, 85 (03) : AB146 - AB146
  • [42] Safety and efficacy of bimekizumab through 2 years in patients with moderate-to-severe plaque psoriasis: longer-term results from the BE SURE randomized controlled trial and the open-label extension from the BE BRIGHT trial
    Thaci, Diamant
    Vender, Ron
    de Rie, Menno A.
    Conrad, Curdin
    Pariser, David M.
    Strober, Bruce
    Vanvoorden, Veerle
    Wang, Maggie
    Madden, Cynthia
    de Cuyper, Dirk
    Kimball, Alexa B.
    BRITISH JOURNAL OF DERMATOLOGY, 2023, 188 (01) : 22 - 31
  • [43] Safety and efficacy of bimekizumab through 2 years in patients with moderate to severe plaque psoriasis: Long-term results from BE SURE randomised controlled trial and BE BRIGHT open-label extension
    Thaci, Diamant
    Vender, Ronald
    de Rie, Menno
    Conrad, Curdin
    Pariser, David
    Strober, Bruce
    Vanvoorden, Veerle
    Peterson, Luke
    Madden, Cynthia
    De Cuyper, Dirk
    Rubel, Diana
    Kimball, Alexa
    AUSTRALASIAN JOURNAL OF DERMATOLOGY, 2022, 63 : 14 - 15
  • [44] Bimekizumab efficacy and safety in Korean patients with moderate to severe plaque psoriasis: A phase 3, randomized, placebo-controlled, double-blinded study
    Youn, Sang Woong
    Jo, Seong Jin
    Park, Chul Jong
    Kim, Dong Hyun
    Shin, Bong Seok
    Jeong, Ki Heon
    Bang, Chul Hwan
    Cross, Nancy
    Thirlwell, Jackie
    Hoepken, Bengt
    JOURNAL OF DERMATOLOGY, 2024, 51 (11): : 1392 - 1403
  • [45] Efficacy and safety of Risankizumab compared with adalimumab in patients with moderate-to-severe plaque psoriasis: Results from the Phase 3 IMMvent trial
    Reich, K.
    Gooderham, M.
    Thaci, D.
    Crowley, J. J.
    Ryan, C.
    Kruger, J. G.
    Tsai, T.
    Flack, M.
    Gu, Y.
    Williams, D. A.
    Thompson, E. H.
    Paul, C.
    EXPERIMENTAL DERMATOLOGY, 2019, 28 (03) : E24 - E25
  • [46] Safety of efalizumab in adults with chronic moderate to severe plaque psoriasis: A phase IIIb, randomized, controlled trial
    Papp, KA
    Bressinck, R
    Fretzin, S
    Goffe, B
    Kempers, S
    Gordon, KB
    Caro, I
    Walicke, PA
    Wang, XL
    Menter, A
    INTERNATIONAL JOURNAL OF DERMATOLOGY, 2006, 45 (05) : 605 - 614
  • [47] Nail outcome improvements with certolizumab pegol in moderate to severe plaque psoriasis: results from phase 3 trials
    Gottlieb, A. B.
    Thaci, D.
    Leonardi, C.
    Poulin, Y.
    Kavanagh, S.
    Boehnlein, M.
    Reich, K.
    JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2019, 33 : 54 - 54
  • [48] Bimekizumab efficacy and safety in patients with moderate to severe plaque psoriasis: Two-year interim results from the open-label extension of the randomized BE RADIANT phase 3b trial
    Strober, Bruce
    Paul, Carle
    Blauvelt, Andrew
    Thaci, Diamant
    Puig, Luis
    Lebwohl, Mark
    White, Katy
    Vanvoorden, Veerle
    Deherder, Delphine
    Gomez, Natalie Nunez
    Eyerich, Kilian
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2023, 89 (03) : 486 - 495
  • [49] Bimekizumab efficacy and safety through 2 years in patients with moderate to severe plaque psoriasis: Analysis of pooled data from five phase 3/3b clinical trials
    Penas, Pablo Fernandez
    Gordon, Kenneth B.
    Armstrong, April W.
    Lebwohl, Mark
    Blauvelt, Andrew
    Paul, Carle
    Wang, Maggie
    Vanvoorden, Veerle
    Madden, Cynthia
    Gomez, Natalie Nunez
    Deherder, Delphine
    Thaci, Diamant
    AUSTRALASIAN JOURNAL OF DERMATOLOGY, 2023, 64 : 20 - 20
  • [50] Improvement in nail psoriasis in the open-label extension of a phase-2 trial of ixekizumab in patients with moderate-to-severe plaque psoriasis
    McKevitt, N.
    Rich, P.
    Langley, R. G.
    Menter, A.
    Krueger, G.
    Zhu, B.
    Wei, H.
    Cameron, G. S.
    Heffernan, M. P.
    AUSTRALASIAN JOURNAL OF DERMATOLOGY, 2015, 56 : 50 - 50
12345